Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Engineered immune cells take on deadliest brain tumors

NCT ID NCT06482905

First seen Jan 07, 2026 · Last updated May 01, 2026 · Updated 13 times

Summary

This early-phase study tests a new treatment called TX103 CAR-T cells for people with a severe and fast-growing brain cancer (grade 4 glioma) that has come back or worsened. The therapy uses a patient's own immune cells, modified in a lab to better recognize and attack cancer cells. The main goals are to check if the treatment is safe and to find the best dose, with 52 adults expected to take part.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIGH-GRADE GLIOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Beijing Tiantan Hospital

    RECRUITING

    Beijing, Beijing Municipality, 100730, China

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Mayo Clinic in Arizona

    RECRUITING

    Phoenix, Arizona, 85054, United States

    Contact

  • Mayo Clinic in Florida

    RECRUITING

    Jacksonville, Florida, 32224, United States

    Contact

  • Mayo Clinic in Rochester

    RECRUITING

    Rochester, Minnesota, 55905, United States

    Contact Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.